Tourmaline Bio, Inc. — Investor Relations & Filings
Filings indexed
336
across all filing types
Latest filing
2025-11-17
Regulatory Filings
Country
US
United States of America
Listing
US
TRML
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with life-altering inflammatory and immune diseases. The company's lead asset is pacibekitug, a monoclonal antibody that targets the interleukin-6 (IL-6) cytokine, a key driver of inflammation. Pacibekitug is being developed as a potential treatment for a range of conditions, with a primary focus on atherosclerotic cardiovascular disease (ASCVD) and other severe autoimmune and inflammatory disorders, aiming to establish a new standard of care in areas with high unmet medical need.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Regulatory Filings 2025 | 2025-11-17 | English | |
| Regulatory Filings 2025 | 2025-11-17 | English | |
| Major Shareholding Notification 2025 | 2025-11-14 | English | |
| FORM 15-12G | 2025-11-07 | English | |
| Director's Dealing 2025 | 2025-10-28 | English | |
| Director's Dealing 2025 | 2025-10-28 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 13320150 | Regulatory Filings 2025 | 2025-11-17 | English | ||
| 13320151 | Regulatory Filings 2025 | 2025-11-17 | English | ||
| 13320152 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13320153 | FORM 15-12G | 2025-11-07 | English | ||
| 13320154 | Director's Dealing 2025 | 2025-10-28 | English | ||
| 13320155 | Director's Dealing 2025 | 2025-10-28 | English | ||
| 13320156 | Director's Dealing 2025 | 2025-10-28 | English | ||
| 13320157 | Director's Dealing 2025 | 2025-10-28 | English | ||
| 13320158 | Director's Dealing 2025 | 2025-10-28 | English | ||
| 13320159 | Director's Dealing 2025 | 2025-10-28 | English | ||
| 13320160 | Director's Dealing 2025 | 2025-10-28 | English | ||
| 13320161 | Director's Dealing 2025 | 2025-10-28 | English | ||
| 13320162 | Director's Dealing 2025 | 2025-10-28 | English | ||
| 13320163 | Director's Dealing 2025 | 2025-10-28 | English | ||
| 13320164 | Director's Dealing 2025 | 2025-10-28 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Tourmaline Bio, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32658/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32658 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32658 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32658 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32658}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Tourmaline Bio, Inc. (id: 32658)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.